Archive

Corporate News back to the archivec-LEcta: European dossiers submitted for approval of new enzymes in the food industry Successful submission of two registration dossiers for food enzymes in Europe. Dossiers were prepared in exclusive ...

Leipzig, March 2, 2021 – c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, can significantly reduce the cost of supplier audits for customers thanks to its recent award of EXCiPACT certification. The certificate confirms compliance with particularly high quality standards in production and distribution. For customers from the pharmaceutical industry in particular, these standards are an important criterion for qualifying suppliers and the closure of contracts. The certification significantly eases cooperation with new and existing customers for c-LEcta. EXCiPACT certification is internationally recognized and confirms that c-LEcta complies with “Good Manufacturing Practice” and “Good Distribution Practice” for pharmaceutical excipients.

c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development has started working with World Courier, an AmerisourceBergen company. With a presence in 50+ countries, World Courier is driven by a commitment to excellence, and provides customized solutions with global reach to increase access to care; making them a highly trusted specialty logistics company for c-LEcta’s customers in the pharmaceutical industry.

Corporate news to the archive c-LEcta grows significantly in fiscal year 2019, strong start in 2020 Significant revenue growth of 114% compared to 2018, EBITDA slightly positive Product business further expanded and organizational growth ...

Corporate news to the archive c-LEcta takes on new industrial partner and successfully continues its development into a product company Expansion of cooperation with industry in the area of process ...

Leipzig, December 10, 2019 – c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development for regulated markets such as the food and pharmaceutical industries, looks back on 15 years of successful company history.

Corporate news to the archive c-LEcta: Successful product business in the first half of 2019 Product business further expanded and portfolio diversified Number of granted patents increases to 80 Sales and shipping to 25 ...

Corporate news to the archive c-LEcta: Financial figures for 2018 underscore successful transformation into a product company Transformation into a product company further advanced Higher diversification of product ...